港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

716.784

+0.8180.11%

漲家數：13

跌家數：17

平家數：4

市盈率：- -

高：728.504

開：715.966

低：704.159

收：715.966

成交量：9,204.19萬

成交額：33.46億

市值：4,587.67億

流通市值：4,074.71億

資料載入中...

總覽新聞資訊

醫藥早參｜藥品價格機制新政出台，創新藥發展環境持續優化

每日经济新闻

定價權迴歸市場！創新藥迎重大政策利好最新高增長潛力股名單出爐

基石藥業-B(02616)擬配售合共1.18億股配售股份淨籌約10.53億港元

港股概念追蹤 | 創新藥板塊迎政策東風國辦發文健全藥品價格形成機制（附概念股）

政策加碼我國創新藥實現自研與出海雙突破

经济参考报

優必選認知功能評估與訓練軟件Cogdo S4獲醫療器械註冊證

創新藥賽道午後回暖，資金連續4個交易日佈局港股通創新藥ETF易方達（159316）

創新藥「加速度」，商保角色重塑：從補充支付到核心參與！

君實生物在珠海成立新醫藥科技公司註冊資本5000萬元

國辦：對創新程度高、臨床價值大的高水平創新藥支持在上市初期制定與高投入、高風險相符的價格

捕捉全球醫藥創新機遇，借道專業工具把握「新質生產力」投資主線

中國首個三組分百白破疫苗獲批，康希諾生物成長邏輯躍升

仿製藥藥企，卻搭上了創新藥的東風

心瑋醫療－Ｂ(06609)股價下跌8.532%，現價港幣$53.6

阿斯达克财经

康方生物(09926)出現大手賣出4.8萬股，成交價$138.4，涉資664.32萬

阿斯达克财经

「明星」抗癌藥中國「七連發」：跨國藥企加速重塑在華商業模式

21世纪经济报道

國家醫療保障局持續開展定點醫藥機構違法違規使用醫保基金自查自糾工作

国家医保局

加速佈局兒童實體瘤治療領域！亞盛醫藥 MDM2-p53 抑制劑APG-115獲CDE納入"星光計劃"

港股勁方醫藥-B盤中升逾22%

每日经济新闻

港股異動 | 綠葉製藥(02186)午前漲近3% 近日自研創新藥LY03020中國Ⅱ期臨床試驗完成首例受試者入組

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":716.78375,"timestamp":1776411300570,"preClose":715.96594,"halted":0,"volume":92041853,"delay":0,"changeRate":0.001142,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0.81781,"latestTime":"04-17 15:35:00","open":715.96594,"high":728.5041,"low":704.15936,"amount":3345786456,"amplitude":0.034003,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1776413400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"pbRate":5.627353,"peRate":-94.073273,"turnoverRate":0.003356,"increases":13,"decrements":17,"flats":3,"marketCap":458767353280,"floatMarketCap":407471170640},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":728.5041,"amplitude":0.034003,"preClose":715.96594,"low":704.15936,"pbRate":"5.627353","latestPrice":716.78375,"volume":92041853,"delay":0,"open":715.96594,"prevYearClose":556.26263,"prevWeekClose":666.249,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":666.249,"twentyDayClose":575.488,"sixtyDayClose":612.872,"secType":"PLATE","market":"HK","turnoverRate":0.003356,"peRate":-94.073273,"marketCap":458767353280,"floatMarketCap":407471170640,"timestamp":1776411300570,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":13,"down":17,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627479134","title":"醫藥早參｜藥品價格機制新政出台，創新藥發展環境持續優化","url":"https://stock-news.laohu8.com/highlight/detail?id=2627479134","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627479134?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 09:41","pubTimestamp":1776217266,"startTime":"0","endTime":"0","summary":"4月14日，港股通生物科技ETF华安（159102）上涨0.61%。成分股中，药明生物上涨5.50%、药明康德上涨1.25%、信达生物下跌0.69%、百济神州下跌1.18%。与此同时，医药ETF华安（512120）上涨0.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705568062.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705568062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","09939","BK1515","06978","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627730054","title":"定價權迴歸市場！創新藥迎重大政策利好 最新高增長潛力股名單出爐","url":"https://stock-news.laohu8.com/highlight/detail?id=2627730054","media":"市场资讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627730054?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 07:46","pubTimestamp":1776210360,"startTime":"0","endTime":"0","summary":"时隔11年，国家层面再次以国务院办公厅名义就药品价格议题发布纲领性文件，标志我国从“分散控费”转向全生命周期、分类施策、全国统一市场的价格治理新阶段。　　4月14日，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，提出14条举措，包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、引导药店合理制定药品零售价格、强化短缺药保供稳价等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2026-04-15/doc-inhupqxi8554462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627342004","title":"基石藥業-B(02616)擬配售合共1.18億股配售股份 淨籌約10.53億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627342004","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627342004?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 07:28","pubTimestamp":1776209318,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，于2026年4月14日，本公司与配售代理订立配售协议，本公司已有条件同意透过配售代理，以每股配售股份8.97港元的价格，向不少于六名承配人配售合共1.18亿股配售股份。配售股份将根据一般授权配发及发行，且无需取得任何股东批准。假设所有1.18亿股配售股份获悉数认购，于配售完成后，配售所得款项总额将为10.58亿港元，配售所得款项净额估计为10.53亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627245420","title":"港股概念追蹤 | 創新藥板塊迎政策東風 國辦發文健全藥品價格形成機制（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2627245420","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627245420?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 07:16","pubTimestamp":1776208598,"startTime":"0","endTime":"0","summary":"意见从4个方面提出14条举措，包括完善重点环节药品价格政策、推动相关主体发挥药品价格发现作用、引导关键领域药品价格保持合理水平、加强药品价格治理。具体举措包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、健全药品集中带量采购价格形成机制、完善药品挂网价格管理。《意见》发布后，市场普遍认为新政将为医药产业特别是创新药带来发展新契机。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0572944931.SGD","LU1242518931.SGD","LU0181495838.USD","LU0516422366.SGD","LU0979878070.USD","BK4585","IE00B0JY6N72.USD","LU0051755006.USD","LU0140636845.USD","LU2045819591.USD","LU2242644610.SGD","SG9999002463.SGD","03347","LU0348735423.USD","LU0320764599.SGD","LU0043850808.USD","LU0348825331.USD","LU0326950275.SGD","LU0417516902.SGD","LU0856984785.SGD","BK1574","LU1046422090.SGD","BK1161","BK1589","BK1583","LU1242518857.USD","LU0052750758.USD","06127","02315","LU0039217434.USD","LU0456827905.SGD","LU0516423091.SGD","159992","LU2039709279.SGD","LU0823426308.USD","BK1141","02359","02269","LU0516422952.EUR","06978","LU0516422440.USD","VXUS","LU0359202008.SGD","LU0588546209.SGD","LU0819121731.USD","LU0327786744.USD","LU0307460666.USD","LU0708995583.HKD","BK1610","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627042403","title":"政策加碼我國創新藥實現 自研與出海雙突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2627042403","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627042403?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 04:41","pubTimestamp":1776199312,"startTime":"0","endTime":"0","summary":"国务院办公厅近日印发《关于健全药品价格形成机制的若干意见》（以下简称《意见》）。多位业内人士表示，《意见》提出的全生命周期药品价格形成机制，为我国创新药产业发展筑牢了政策根基，不仅规范了药品定价秩序，更稳定了企业创新投入预期，为行业有序竞争、长期可持续发展注入强劲动力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153704971265.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153704971265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441633","title":"優必選認知功能評估與訓練軟件Cogdo S4獲醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441633","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627441633?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 20:48","pubTimestamp":1776170880,"startTime":"0","endTime":"0","summary":"人民财讯4月14日电，据优必选消息，近日，优必选认知功能评估与训练软件CogdoS4获医疗器械注册证，正式成为具备临床准入资质的数字疗法产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704696691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK4588","BK1222","09880","BK1100","BK1583","BK1183","BK1613","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627434024","title":"創新藥賽道午後回暖，資金連續4個交易日佈局港股通創新藥ETF易方達（159316）","url":"https://stock-news.laohu8.com/highlight/detail?id=2627434024","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627434024?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 19:43","pubTimestamp":1776167023,"startTime":"0","endTime":"0","summary":"4月14日，创新药赛道午后回暖，指数层面，恒生港股通创新药指数上涨0.3%，中证创新药产业指数上涨0.7%，港股通创新药ETF易方达全天获3100万份净申购。Wind数据显示，该ETF此前已连续3个交易日获资金净流入，合计9000万元。兴业证券表示，中国创新药具备高效率、低成本的开发优势，在热门技术赛道如 ADC、双抗、小核酸等具备竞争优势，有望持续展现行业竞争力。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/14/20260414741546.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/14/20260414741546.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260414/32143378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159316","BK1161","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627458354","title":"創新藥「加速度」，商保角色重塑：從補充支付到核心參與！","url":"https://stock-news.laohu8.com/highlight/detail?id=2627458354","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627458354?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 19:31","pubTimestamp":1776166260,"startTime":"0","endTime":"0","summary":"　　在我国多层次医疗保障体系持续深化完善、医药创新产业迈向高质量发展的关键阶段，商业健康险的行业定位正发生根本性转变。这是国办文件中首次如此明确且系统地将商业健康险置于创新药支付体系的核心位置，标志着商保参与医药创新的制度框架全面成型。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2026-04-14/doc-inhunpmu1494189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627486614","title":"君實生物在珠海成立新醫藥科技公司 註冊資本5000萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627486614","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627486614?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 18:46","pubTimestamp":1776163560,"startTime":"0","endTime":"0","summary":"本报讯天眼查App显示，近日，珠海君实生物医药科技有限公司成立，注册资本5000万元，经营范围包括医学研究和试验发展、技术进出口、货物进出口等，由君实生物全资持股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704576637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1515","159938","01877","BK1574","BK1161","688180","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627411595","title":"國辦：對創新程度高、臨床價值大的高水平創新藥 支持在上市初期制定與高投入、高風險相符的價格","url":"https://stock-news.laohu8.com/highlight/detail?id=2627411595","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627411595?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 17:03","pubTimestamp":1776157380,"startTime":"0","endTime":"0","summary":"　　4月14日，国务院办公厅发布关于健全药品价格形成机制的若干意见。对创新程度高、临床价值大的高水平创新药，支持在上市初期制定与高投入、高风险相符的价格，在一定时期内保持价格相对稳定。对改良新药等，鼓励引导制定与患者获益相匹配的价格。对通用名药等其他新上市药品，引导医药企业参照同通用名、同作用机制、同功能主治药品价格合理定价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-04-14/doc-inhunicu4772129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","IPOS","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627413754","title":"捕捉全球醫藥創新機遇，借道專業工具把握「新質生產力」投資主線","url":"https://stock-news.laohu8.com/highlight/detail?id=2627413754","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627413754?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 15:49","pubTimestamp":1776152940,"startTime":"0","endTime":"0","summary":"　　2026年政府工作报告首次将生物医药明确定位为“新兴支柱产业”，并将其纳入“十五五”规划，将其深度融入发展“新质生产力”的宏伟蓝图，这不仅是对一个行业发展的战略定位，更是对中国未来产业升级方向的清晰指引。工银瑞信基金旗下拥有一系列历经市场周期检验、聚焦医药健康领域的主题基金，为投资者布局这一“新兴支柱产业”提供了多层次、系统化的工具选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-04-14/doc-inhunavy1629906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159938","09939","162414","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627184954","title":"中國首個三組分百白破疫苗獲批，康希諾生物成長邏輯躍升","url":"https://stock-news.laohu8.com/highlight/detail?id=2627184954","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627184954?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 15:19","pubTimestamp":1776151191,"startTime":"0","endTime":"0","summary":"盼康欣®的获批，不仅是康希诺生物产品矩阵中又一款重磅新品的落地，深层则是对公司创新技术平台厚度、管线梯度构建能力与商业化体系效率的集中验证。","market":"us","thumbnail":"https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4407500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159646","BK1574","BK1191","BK1515","688185","06185","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627418921","title":"仿製藥藥企，卻搭上了創新藥的東風","url":"https://stock-news.laohu8.com/highlight/detail?id=2627418921","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627418921?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 15:14","pubTimestamp":1776150866,"startTime":"0","endTime":"0","summary":"就连仿制药企#津药药业，都因搭上了创新药的东风，股价接连上涨。来源：东方财富官网-津药药业 4月8日，公司发布“公司目前研发以仿制药为主，无在研创新药项目，相关炒作存在明显误读”的公告后，公司股价才有所降温。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1776132638383230835","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627185624","title":"心瑋醫療－Ｂ(06609)股價下跌8.532%，現價港幣$53.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2627185624","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627185624?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 14:55","pubTimestamp":1776149700,"startTime":"0","endTime":"0","summary":"[下跌股]心玮医疗－Ｂ(06609) 股价在下午02:55比前收市价下跌8.532%，现股价为港币$53.6。至目前为止，今日最高价为$60.3，而最低价为$53.6。总成交量为11.11万股，总成交金额为港币$617.331万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604141864/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604141864/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1587","06609","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627185574","title":"康方生物(09926)出現大手賣出4.8萬股，成交價$138.4，涉資664.32萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2627185574","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627185574?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 14:53","pubTimestamp":1776149580,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在下午02:53出现大手卖出，成交量为4.8万，成交价为港币$138.4，涉资664.32万。至目前为止，股价升0.435%，今日最高价为$140.3，而最低价为$136.2，总成交量为347.994万股，总成交金额港币$4.801亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604146536/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604146536/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00BPRC5H50.USD","LU0348827113.USD","LU0417516738.SGD","LU2476274308.USD","LU0348767384.USD","LU1961090484.USD","09926","BK1574","LU0348766576.USD","LU2476274720.SGD","LU0348784397.USD","LU2399975544.HKD","LU0634319403.HKD","LU0540923850.HKD","LU0348825331.USD","LU0348783233.USD","LU1794554557.SGD","LU0417516902.SGD","IE00B543WZ88.USD","BK1161","LU0561508036.HKD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2778985437.USD","LU0348735423.USD","LU1720050803.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627494406","title":"「明星」抗癌藥中國「七連發」：跨國藥企加速重塑在華商業模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2627494406","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627494406?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 13:17","pubTimestamp":1776143820,"startTime":"0","endTime":"0","summary":"近日，由阿斯利康与第一三共共同开发与商业化的德曲妥珠单抗在中国取得新突破：其序贯THP疗法用于HER2阳性早期乳腺癌新辅助治疗的适应症实现“全球首批”，中国患者成为全球最早受益于这一创新疗法的群体。这并非德曲妥珠单抗在中国的首次亮相。自2023年首次获批以来，这款被称为“大魔王”的抗体偶联药物（ADC）在中国接连拿下七项适应症，覆盖乳腺癌、肺癌、胃癌等多个领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704221860.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704221860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4080","06978","ADC","BK4231","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627449114","title":"國家醫療保障局持續開展定點醫藥機構違法違規使用醫保基金自查自糾工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2627449114","media":"国家医保局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627449114?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 12:30","pubTimestamp":1776141000,"startTime":"0","endTime":"0","summary":"国家医保局已下发2026年定点医药机构违法违规使用医保基金典型问题清单，各地医保部门已于3月底前结合本地医保政策、诊疗项目规范，对问题清单进行细化完善。5月起，国家医保局将组织对各地自查自纠情况进行抽查复查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-14/doc-inhumwqc9085405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK1574","BK1161","09939","BK1515","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627497821","title":"加速佈局兒童實體瘤治療領域！亞盛醫藥 MDM2-p53 抑制劑APG-115獲CDE納入\"星光計劃\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2627497821","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627497821?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 12:14","pubTimestamp":1776140040,"startTime":"0","endTime":"0","summary":"此次APG-115获纳入\"星光计划\"，将有助于公司与CDE的进一步紧密沟通，获得儿童人群研究过程中技术问题的针对性指导。APG-115此次获纳入CDE'星光计划'，是国家药监机构对该品种临床价值与研发前景的高度认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4933478_ZH33478_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","CDE","LU1223082519.USD","LU1923622291.USD","AAPG","BK4129","APG","LU2125909759.SGD","LU1223082196.USD","BK1161","LU2125909916.SGD","BK4017","06855","BK4139","LU1223083913.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627949947","title":"港股勁方醫藥-B盤中升逾22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627949947","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627949947?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 12:01","pubTimestamp":1776139262,"startTime":"0","endTime":"0","summary":"【港股劲方医药-B盘中涨超22%】4月14日，劲方医药-B(02595.HK)盘中涨超22%，截至发稿涨14.37%，报44.88港元，成交额1.94亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704180475.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704180475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","VXUS","159938","02595","BK1161","BK4585","BK1515","BK4588","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627983499","title":"港股異動 | 綠葉製藥(02186)午前漲近3% 近日自研創新藥LY03020中國Ⅱ期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2627983499","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627983499?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 11:54","pubTimestamp":1776138882,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，绿叶制药午前涨近3%，截至发稿，涨2.52%，报2.85港元，成交额5323.6万港元。消息面上，近日，绿叶制药发布公告，本集团自主研发的创新药LY03020的中国Ⅱ期临床已完成首例患者入组。此前，LY03020亦已在美国获准开展临床试验，是本集团在中国和海外同步开发的又一款中枢神经系统治疗领域的创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1606","BK1574","BK4588","159992","06978","02186","BK1161","BK1191","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":5,"totalSize":247,"code":"91000000","status":"200"}]}}